Drug Profile


Alternative Names: Butena; Butenafide; Butenafide hydrochloride; Butenafine hydrochloride; Dermacom; Dermax; Dr. Scholl's; Fintop; Funcid; Ingebut; KP 363; Lotrimin Ultra; Mentax; Volley; Zaxem

Latest Information Update: 25 Mar 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Kaken Pharmaceutical
  • Developer Kaken Pharmaceutical; Merck & Co
  • Class Antifungals; Naphthalenes; Small molecules
  • Mechanism of Action Squalene monooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Marketed Mycoses; Onychomycosis; Pityriasis versicolor; Tinea corporis; Tinea cruris; Tinea pedis

Most Recent Events

  • 10 Jul 2007 No development reported - Phase-III for Onychomycosis in USA (PO)
  • 07 Sep 2004 Added Sinphar and Hanlim to Company table
  • 10 Jul 2004 Launched for Mycoses in China (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top